Myriad Genetics盐湖城与San Diego合作,创建了基于套件的Myriad的Myriad的MyChoice Companion诊断(CDX)测试。

“增加对我们的产品和更好的服务患者和医疗保健提供者是亚博体育最新app下载我们使命的关键组成部分,以提高结果和我们的转型计划以推动增长。无数和Illumina之间的协议结合了伴侣诊断和下一代测序来推进肿瘤样本的综合基因组分析,并在肿瘤学中推动改善的结果,“无数遗传学总裁兼首席执行官Paul J. Diaz说。亚博足彩app苹果版“这项合作反映了我们对伊利姆纳等高口径医疗领导人合作的越来越关注,为肿瘤科学市场带来创新的解决方案。”

Myriad和Illumina之间的战略合作伙伴关系包括illumina的有限的独家协议,为国际市场提供基于套件的MyChoice CDX测试版本。Illumina将利用其测序仪器安装基础和知识,从而提高市场采用其Trusight肿瘤500强的下一代测序试验,以在全球范围内开发和商业化分布式套件,以评估同源重组缺损(HRD)以及Myriad扩展访问的其他专有生物标志物以及其他专有生物标志物。和extends the reach of myChoice CDx through Myriad’s services offering.

“Illumina致力于提供功率精密肿瘤学的创新诊断工具,”Illumina的首席医务官员Phil Febbo说。“越来越多的PARP抑制剂治疗方法对HRD患者的更广泛的群体是令人遗憾的是,在我们与Myriad Genetics的工作中,作为医疗保健的未来,通过基于分子的测试来通过标准化,最好的课程测试,在MyChoice CDX测试中改善患者结果。”

The myChoice CDx offering – through Myriad’s world-class laboratory – is the only companion diagnostic test extensively validated in clinical trials to predict response to poly-ADP ribose polymerase (PARP) inhibitor drugs commonly used in the treatment of ovarian, breast, pancreatic, and prostate cancer. It utilizes proprietary technologies to measure genomic instability within tumors and help predict drug response. myChoice CDx test recently received both European CE Marking and Japanese regulatory approval for use as a companion diagnostic with Lynparza (olaparib) for first-line maintenance treatment in ovarian cancer in conjunction with bevacizumab. Lynparza is a PARP inhibitor jointly developed and commercialized by AstraZeneca and Merck.

有关更多信息,请访问无数遗传学illumina

特色图片:PC-3人前列腺癌细胞,用Coomassie蓝色染色,在差动干扰造影显微镜下。